Hospital
Beavercreek Medical Center
Beavercreek Medical Center was paid $30.49M by Medicaid between Jan 2018 and Dec 2024, across 300 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 18% of everything it billed.
33Billing provider infoBEAVERCREEK MEDICAL CENTER
BEAVERCREEK, OH 45431
BEAVERCREEK, OH 45431
33aNPI1760764849assigned 09/14/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.49M
24GClaims793,860
24DCodes billed300
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#38 of 101
Median peer was paid$22.32M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KO, TIMOTHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,744 | $1.25M | |
| 2019 | 39,731 | $1.47M | |
| 2020 | 26,768 | $1.27M | |
| 2021 | 43,037 | $1.83M | |
| 2022 | 85,197 | $3.64M | |
| 2023 | 323,076 | $12.58M | |
| 2024incomplete | 243,307 | $8.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 17,775 | 13,563 | $5.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 38,544 | 34,930 | $5.33M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 44,044 | 39,880 | $4.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 15,037 | 12,892 | $2.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 5,525 | 4,632 | $1.32M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 5,185 | 4,391 | $1.25M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 4,040 | 3,383 | $1.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 4,857 | 4,502 | $617K |
| 59025 | Fetal non-stress test | 2.0% | 3,907 | 2,820 | $596K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 2,535 | 2,230 | $552K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 5,120 | 4,173 | $497K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 4,027 | 3,154 | $463K |
288 more codes
| G0378 | Hospital observation service, per hour | 1.3% | 5,301 | $390K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 3,055 | $387K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,425 | $362K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 2,825 | $331K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,843 | $285K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 56,706 | $247K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,846 | $210K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12,756 | $205K |
| 20553 | <1% | 1,381 | $150K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 852 | $141K |
| 76642 | <1% | 1,087 | $135K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,867 | $117K |
| 70496 | <1% | 578 | $115K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,413 | $107K |
| 76830 | Ultrasound, transvaginal | <1% | 1,387 | $102K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 892 | $97K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,083 | $95K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 899 | $94K |
| 93356 | <1% | 402 | $94K | |
| 47562 | <1% | 42 | $84K | |
| 12001 | <1% | 527 | $82K | |
| 93971 | <1% | 1,220 | $77K | |
| 20610 | <1% | 563 | $74K | |
| 72131 | <1% | 1,377 | $70K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,864 | $66K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 256 | $57K |
| 71250 | <1% | 781 | $55K | |
| 93970 | <1% | 448 | $54K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 138 | $53K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,297 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 67,172 | $49K |
| 10060 | <1% | 289 | $47K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,193 | $46K |
| 82805 | <1% | 1,940 | $46K | |
| 70491 | <1% | 156 | $45K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,362 | $40K |
| 97165 | <1% | 673 | $38K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,706 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,285 | $35K |
| 97162 | <1% | 988 | $35K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,880 | $34K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 152 | $31K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,255 | $31K |
| 96367 | <1% | 867 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,969 | $30K |
| 84484 | <1% | 21,333 | $30K | |
| 76536 | <1% | 253 | $27K | |
| 73130 | <1% | 1,734 | $27K | |
| 93017 | <1% | 338 | $27K | |
| 86780 | <1% | 899 | $26K | |
| 77065 | Tomosynthesis, mammo | <1% | 737 | $26K |
| 73562 | <1% | 1,017 | $25K | |
| 97161 | <1% | 399 | $25K | |
| 73030 | <1% | 1,614 | $24K | |
| 97166 | <1% | 750 | $24K | |
| 87529 | <1% | 3,132 | $23K | |
| 80076 | <1% | 17,982 | $23K | |
| J3490 | Unclassified drugs | <1% | 6,706 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,574 | $23K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 151 | $22K |
| 86850 | <1% | 1,002 | $22K | |
| 77066 | Tomosynthesis, mammo | <1% | 628 | $21K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 758 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,965 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,182 | $19K |
| 12011 | <1% | 117 | $18K | |
| 86900 | <1% | 1,322 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 149 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 101 | $17K |
| 19083 | <1% | 27 | $17K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 125 | $17K |
| 73630 | <1% | 1,998 | $17K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 145 | $16K |
| 90715 | <1% | 1,119 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,969 | $16K |
| 94010 | <1% | 227 | $15K | |
| 80069 | <1% | 2,629 | $15K | |
| 72100 | <1% | 659 | $15K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15,175 | $15K |
| 70486 | <1% | 599 | $14K | |
| 99152 | <1% | 555 | $14K | |
| 12002 | <1% | 99 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 581 | $13K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,891 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,890 | $13K |
| 80061 | Lipid panel | <1% | 1,149 | $12K |
| 94726 | <1% | 185 | $12K | |
| 72128 | <1% | 619 | $12K | |
| 74018 | <1% | 701 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,140 | $11K |
| 73110 | <1% | 948 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,322 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,355 | $10K |
| 76870 | <1% | 140 | $10K | |
| 73610 | <1% | 1,619 | $10K | |
| 84702 | <1% | 1,597 | $10K | |
| 62323 | <1% | 35 | $10K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 990 | $10K |
| 86803 | <1% | 472 | $10K | |
| 72132 | <1% | 114 | $9K | |
| 81001 | <1% | 25,673 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,292 | $9K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 780 | $9K |
| 84439 | <1% | 792 | $9K | |
| 73502 | <1% | 725 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 332 | $9K |
| 73560 | <1% | 1,167 | $9K | |
| 74420 | <1% | 81 | $8K | |
| 82607 | <1% | 595 | $8K | |
| 85027 | <1% | 2,655 | $8K | |
| 64999 | <1% | 104 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 279 | $7K |
| 70498 | <1% | 583 | $7K | |
| 94729 | <1% | 187 | $7K | |
| 72040 | <1% | 172 | $6K | |
| 82728 | <1% | 518 | $6K | |
| 83735 | <1% | 4,934 | $6K | |
| 74183 | <1% | 27 | $6K | |
| 83880 | <1% | 2,097 | $5K | |
| 72141 | <1% | 27 | $5K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $5K |
| 86901 | <1% | 1,322 | $5K | |
| 96376 | <1% | 3,300 | $5K | |
| 88307 | <1% | 45 | $4K | |
| 83690 | <1% | 15,644 | $4K | |
| 73700 | <1% | 63 | $4K | |
| 96368 | <1% | 231 | $4K | |
| 87340 | <1% | 289 | $4K | |
| 85610 | <1% | 3,308 | $4K | |
| 86762 | <1% | 182 | $4K | |
| 73080 | <1% | 508 | $4K | |
| 81025 | <1% | 11,538 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 289 | $4K |
| 83540 | <1% | 537 | $4K | |
| 76775 | <1% | 56 | $4K | |
| 88341 | <1% | 82 | $4K | |
| 97116 | <1% | 132 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $4K |
| 87077 | <1% | 1,863 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 150 | $3K |
| 73590 | <1% | 625 | $3K | |
| 73140 | <1% | 259 | $3K | |
| 83550 | <1% | 520 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 228 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $3K |
| 64488 | <1% | 20 | $3K | |
| 84112 | <1% | 61 | $3K | |
| 82950 | <1% | 183 | $3K | |
| 94667 | <1% | 94 | $3K | |
| 01999 | <1% | 374 | $3K | |
| 29125 | <1% | 700 | $3K | |
| 87634 | <1% | 905 | $2K | |
| 87081 | <1% | 104 | $2K | |
| 73090 | <1% | 435 | $2K | |
| 71271 | <1% | 14 | $2K | |
| 85378 | <1% | 2,682 | $2K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,493 | $2K |
| 82746 | <1% | 481 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,721 | $2K |
| 80320 | <1% | 200 | $2K | |
| 81003 | <1% | 4,545 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 670 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 749 | $2K |
| 87186 | <1% | 1,524 | $2K | |
| 83605 | <1% | 3,150 | $2K | |
| 92610 | <1% | 84 | $2K | |
| 71101 | <1% | 412 | $2K | |
| 76801 | <1% | 41 | $1K | |
| 93880 | <1% | 16 | $1K | |
| 84100 | <1% | 740 | $1K | |
| 82575 | <1% | 182 | $1K | |
| 87210 | <1% | 1,139 | $1K | |
| 84145 | <1% | 1,831 | $1K | |
| 85651 | <1% | 821 | $1K | |
| 85007 | <1% | 1,335 | $1K | |
| 85014 | <1% | 314 | $1K | |
| 72110 | <1% | 26 | $1K | |
| 77080 | <1% | 16 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,686 | $966.20 |
| 77002 | <1% | 1,167 | $956.74 | |
| 82248 | <1% | 360 | $948.85 | |
| 87040 | <1% | 2,915 | $943.28 | |
| 00840 | <1% | 184 | $928.00 | |
| 85018 | <1% | 475 | $859.21 | |
| 86140 | <1% | 100 | $739.09 | |
| 82550 | <1% | 797 | $739.07 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,206 | $734.71 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,678 | $706.29 |
| 87070 | <1% | 192 | $699.31 | |
| 86141 | <1% | 288 | $658.99 | |
| 84156 | <1% | 200 | $647.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,954 | $638.03 |
| 86703 | <1% | 41 | $605.50 | |
| G0008 | Administration of influenza virus vaccine | <1% | 52 | $601.12 |
| 73552 | <1% | 163 | $599.92 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,017 | $593.11 |
| 84132 | <1% | 654 | $527.82 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,298 | $418.54 |
| 82330 | <1% | 278 | $415.92 | |
| 82140 | <1% | 328 | $407.59 | |
| 90686 | <1% | 23 | $380.81 | |
| 72170 | <1% | 164 | $361.80 | |
| 73620 | <1% | 13 | $359.43 | |
| 85730 | <1% | 847 | $349.88 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 521 | $348.87 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 929 | $346.75 |
| 82043 | <1% | 66 | $337.41 | |
| 73564 | <1% | 12 | $335.41 | |
| 82105 | <1% | 12 | $313.18 | |
| 84703 | <1% | 677 | $308.50 | |
| 72072 | <1% | 15 | $276.14 | |
| 86308 | <1% | 142 | $273.87 | |
| 82947 | <1% | 22 | $269.12 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,791 | $257.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 762 | $249.46 |
| 84550 | <1% | 73 | $243.93 | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 81 | $236.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,468 | $233.23 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 43 | $217.24 |
| 88342 | <1% | 364 | $205.59 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,962 | $171.35 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 486 | $167.58 |
| 86592 | <1% | 14 | $162.56 | |
| 82010 | <1% | 637 | $158.69 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,441 | $156.49 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 173 | $140.22 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,428 | $137.20 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 51 | $136.34 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 73 | $135.88 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,096 | $128.61 |
| 85049 | <1% | 155 | $122.17 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 781 | $114.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,348 | $113.74 |
| 82570 | <1% | 16 | $110.19 | |
| 87205 | <1% | 244 | $107.51 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 785 | $99.93 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 212 | $96.33 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 862 | $77.74 |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 444 | $75.25 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 664 | $64.27 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,027 | $59.68 |
| J2704 | Injection, propofol, 10 mg | <1% | 998 | $57.76 |
| 73060 | <1% | 15 | $54.81 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,089 | $40.25 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 785 | $38.23 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 174 | $26.95 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 286 | $25.88 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 157 | $25.32 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 59 | $23.48 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 552 | $22.79 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 43 | $18.52 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 965 | $16.08 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 750 | $13.98 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 22 | $8.68 |
| 51702 | <1% | 33 | $8.20 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 163 | $6.65 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 461 | $6.45 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 23 | $5.44 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 144 | $4.57 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 320 | $1.72 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 446 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 53 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 124 | $0.00 |
| 00300 | 0% | 26 | $0.00 | |
| 72129 | 0% | 19 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 260 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 141 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 59 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 24 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 38 | $0.00 |
| 00910 | 0% | 22 | $0.00 | |
| 15853 | 0% | 27 | $0.00 | |
| 85347 | 0% | 21 | $0.00 | |
| C1769 | Guide wire | 0% | 690 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 56 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 258 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 142 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 171 | $0.00 |
| 88304 | 0% | 563 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 311 | $0.00 |
| 94760 | 0% | 432 | $0.00 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 24 | $0.00 |
| 94761 | 0% | 14 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 68 | $0.00 |
| 00790 | 0% | 34 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 12 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKO, TIMOTHY (KETTERING HEALTH CFO)
| Provider | Location | Paid |
|---|---|---|
| Dayton Osteopathic Hospital | Dayton, OH | $111.27M |
| Alliance Physicians INC | Kettering, OH | $38.76M |
| Kettering Medical Center | Kettering, OH | $37.96M |
| The Fort Hamilton Hospital | Hamilton, OH | $27.06M |
| Kettering Medical Center | Miamisburg, OH | $20.00M |
| Greene Memorial Hospital INC | Xenia, OH | $11.31M |
| Kettering Medical Center | Troy, OH | $10.83M |
| Kettering Independent Medical Group INC | Miamisburg, OH | $8.39M |
| Kettering Affiliated Health Services | Miamisburg, OH | $2.12M |
| Greene Memorial Hospital, INC. | Jamestown, OH | $1.53M |
| Alliance Physicians INC | Moraine, OH | $1.42M |
| Alliance Physicians INC | Huber Heights, OH | $1.06M |
| Greene Memorial Hospital INC | Yellow Springs, OH | $843K |
| Alliance Physicians INC | Miamisburg, OH | $744K |
| Greene Memorial Hospital INC | Cedarville, OH | $703K |
| Alliance Physicians INC | Xenia, OH | $645K |
| Alliance Physicians INC | Springboro, OH | $616K |
| Alliance Physicians INC | Kettering, OH | $599K |
| Sycamore Primary Care Group | Miamisburg, OH | $564K |
| Alliance Physicians INC | Beavercreek, OH | $486K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.